Compound K, a ginsenoside metabolite, inhibits colon cancer growth via multiple pathways including p53-p21 interactions

International Journal of Molecular Sciences

Volumn 14, Issue 2, 2013, Pages 2980-2995

  Zhang, Zhiyu ^a,b   Du, Guang Jian ^a,b   Wang, Chong Zhi ^a,b   Wen, Xiao Dong ^a,b   Calway, Tyler ^b   Li, Zejuan ^c   He, Tong Chuan ^b   Du, Wei ^d   Bissonnette, Marc ^e   Musch, Mark W ^e   Chang, Eugene B ^e   Yuan, Chun Su ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c SECTION OF HEMATOLOGY ONCOLOGY   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

Author keywords

Cell cycle arrest; Colorectal cancer; Compound K; Ginsenoside; P53 p21; Xenograft

Indexed keywords

20 O BETA DEXTRO GLUCOPYRANOSYL 20 PROTOPANAXADIOL; ATM PROTEIN; CELL CYCLE PROTEIN; CELL CYCLE PROTEIN 25A; CYCLIN D1; CYCLIN D3; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; PROTEIN P15; PROTEIN P21; PROTEIN P27; PROTEIN P53; PROTOPANAXADIOL; SMAD3 PROTEIN; TRANSCRIPTION FACTOR FKHRL1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL STRAIN HCT116; CELL STRAIN HT29; COLON CANCER; COLORECTAL CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DOSE COMPARISON; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION INITIATION; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING;

EID: 84875108087     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms14022980     Document Type: Article

References (50)

1. Arber, N.; Levin, B. Chemoprevention of colorectal cancer: Ready for routine use? Recent Results Cancer Res. 2005, 166, 213-230.
2. Rodriguez, M.; Du, G.J.; Wang, C.Z.; Yuan, C.S. Letter to the editor: Panaxadiol's anticancer activity is enhanced by epicatechin. Am. J. Chin. Med. 2010, 38, 1233-1235.
3. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Thun, M.J. Cancer statistics, 2009. CA Cancer J. Clin. 2009, 59, 225-249.
4. Siegel, R.; Naishadham, D.; Jemal, A. Cancer statistics, 2012. CA Cancer J. Clin. 2012, 62, 10-29.
5. Wils, J.; O'Dwyer, P.; Labianca, R. Adjuvant treatment of colorectal cancer at the turn of the century: European and US perspectives. Ann. Oncol. 2001, 12, 13-22.
6. Segal, N.H.; Saltz, L.B. Evolving treatment of advanced colon cancer. Annu. Rev. Med. 2009, 60, 207-219.
7. Thomasset, S.C.; Berry, D.P.; Garcea, G.; Marczylo, T.; Steward, W.P.; Gescher, A.J. Dietary polyphenolic phytochemicals-Promising cancer chemopreventive agents in humans? A review of their clinical properties. Int. J. Cancer 2007, 120, 451-458.
8. Xu, Z.; Chen, X.; Zhong, Z.; Chen, L.; Wang, Y. Ganoderma lucidum polysaccharides: Immunomodulation and potential anti-tumor activities. Am. J. Chin. Med. 2011, 39, 15-27.
9. Qi, L.W.; Wang, C.Z.; Yuan, C.S. Isolation and analysis of ginseng: Advances and challenges. Nat. Prod. Rep. 2011, 28, 467-495.
10. Qi, L.W.; Wang, C.Z.; Du, G.J.; Zhang, Z.Y.; Calway, T.; Yuan, C.S. Metabolism of ginseng and its interactions with drugs. Curr. Drug. Metab. 2011, 12, 818-822.
11. Wang, H.Y.; Qi, L.W.; Wang, C.Z.; Li, P. Bioactivity enhancement of herbal supplements by intestinal microbiota focusing on ginsenosides. Am. J. Chin. Med. 2011, 39, 1103-1115.
12. Wang, C.Z.; Kim, K.E.; Du, G.J.; Qi, L.W.; Wen, X.D.; Li, P.; Bauer, B.A.; Bissonnette, M.B.; Musch, M.W.; Chang, E.B.; Yuan, C.S. Ultra-performance liquid chromatography and time-of-flight mass spectrometry analysis of ginsenoside metabolites in human plasma. Am. J. Chin. Med. 2011, 39, 1161-1171.
13. Akao, T.; Kanaoka, M.; Kobashi, K. Appearance of compound K, a major metabolite of ginsenoside Rb1 by intestinal bacteria, in rat plasma after oral administration-Measurement of compound K by enzyme immunoassay. Biol. Pharm. Bull. 1998, 21, 245-249.
14. Hasegawa, H.; Sung, J.H.; Matsumiya, S.; Uchiyama, M. Main ginseng saponin metabolites formed by intestinal bacteria. Plant. Med. 1996, 62, 453-457.
15. Oh, S.H.; Lee, B.H. A ginseng saponin metabolite-induced apoptosis in HepG2 cells involves a mitochondria-mediated pathway and its downstream caspase-8 activation and Bid cleavage. Toxicol. Appl. Pharmacol. 2004, 194, 221-229.
16. Ming, Y.L.; Song, G.; Chen, L.H.; Zheng, Z.Z.; Chen, Z.Y.; Ouyang, G.L.; Tong, Q.X. Anti-proliferation and apoptosis induced by a novel intestinal metabolite of ginseng saponin in human hepatocellular carcinoma cells. Cell Biol. Int. 2007, 31, 1265-1273.
17. Chae, S.; Kang, K.A.; Chang, W.Y.; Kim, M.J.; Lee, S.J.; Lee, Y.S.; Kim, H.S.; Kim, D.H.; Hyun, J.W. Effect of compound K, a metabolite of ginseng saponin, combined with.-ray radiation in human lung cancer cells in vitro and in vivo. J. Agric. Food Chem. 2009, 57, 5777-5782.
18. Kim do, Y.; Park, M.W.; Yuan, H.D.; Lee, H.J.; Kim, S.H.; Chung, S.H. Compound K induces apoptosis via CAMK-IV/AMPK pathways in HT-29 colon cancer cells. J. Agric. Food Chem. 2009, 57, 10573-10578.
19. Yu, H.M.; Wang, T.C. Mechanism of cisplatin resistance in human urothelial carcinoma cells. Food Chem. Toxicol. 2012, 50, 1226-1237.
20. Jung, S.H.; Woo, M.S.; Kim, S.Y.; Kim, W.K.; Hyun, J.W.; Kim, E.J.; Kim, D.H.; Kim, H.S. Ginseng saponin metabolite suppresses phorbol ester-induced matrix metalloproteinase-9 expression through inhibition of activator protein-1 and mitogen-activated protein kinase signaling pathways in human astroglioma cells. Int. J. Cancer 2006, 118, 490-497.
21. Lee, S.J.; Sung, J.H.; Moon, C.K.; Lee, B.H. Antitumor activity of a novel ginseng saponin metabolite in human pulmonary adenocarcinoma cells resistant to cisplatin. Cancer Lett. 1999, 144, 39-43.
22. Igney, F.H.; Krammer, P.H. Death and anti-death: Tumour resistance to apoptosis. Nat. Rev. Cancer 2002, 2, 277-288.
23. Agarwal, M.K.; Hastak, K.; Jackson, M.W.; Breit, S.N.; Stark, G.R.; Agarwal, M.L. Macrophage inhibitory cytokine 1 mediates a p53-dependent protective arrest in S phase in response to starvation for DNA precursors. Proc. Natl. Acad. Sci. USA 2006, 103, 16278-16283.
24. Dougherty, U.; Mustafi, R.; Wang, Y.; Musch, M.W.; Wang, C.Z.; Konda, V.J.; Kulkarni, A.; Hart, J.; Dawson, G.; Kim, K.E.; et al. American ginseng suppresses Western diet-promoted tumorigenesis in model of inflammation-associated colon cancer: Role of EGFR. BMC Complement Altern. Med. 2011, 11, 111.
25. Park, J.A.; Lee, K.Y.; Oh, Y.J.; Kim, K.W.; Lee, S.K. Activation of caspase-3 protease via a Bcl-2-insensitive pathway during the process of ginsenoside Rh2-induced apoptosis. Cancer Lett. 1997, 121, 73-81.
26. Shinkai, K.; Akedo, H.; Mukai, M.; Imamura, F.; Isoai, A.; Kobayashi, M.; Kitagawa, I. Inhibition of in vitro tumor cell invasion by ginsenoside Rg3. Jpn. J. Cancer Res. 1996, 87, 357-362.
27. Hwang, J.W.; Oh, J.H.; Yoo, H.S.; Lee, Y.W.; Cho, C.K.; Kwon, K.R.; Yoon, J.H.; Park, J.; Her, S.; Lee, Z.W.; et al. Mountain ginseng extract exhibits anti-lung cancer activity by inhibiting the nuclear translocation of NF-.B. Am. J. Chin. Med. 2012, 40, 187-202.
28. Lee, I.K.; Kang, K.A.; Lim, C.M.; Kim, K.C.; Kim, H.S.; Kim, D.H.; Kim, B.J.; Chang, W.Y.; Choi, J.H.; Hyun, J.W. Compound K, a metabolite of ginseng saponin, induces mitochondria-dependent and caspase-dependent apoptosis via the generation of reactive oxygen species in human colon cancer cells. Int. J. Mol. Sci. 2010, 11, 4916-4931.
29. Hu, C.; Song, G.; Zhang, B.; Liu, Z.; Chen, R.; Zhang, H.; Hu, T. Intestinal metabolite compound K of panaxoside inhibits the growth of gastric carcinoma by augmenting apoptosis via Bid-mediated mitochondrial pathway. J. Cell Mol. Med. 2012, 16, 96-106.
30. Kang, K.A.; Kim, Y.W.; Kim, S.U.; Chae, S.; Koh, Y.S.; Kim, H.S.; Choo, M.K.; Kim, D.H.; Hyun, J.W. G1 phase arrest of the cell cycle by a ginseng metabolite, compound K, in U937 human monocytic leukamia cells. Arch. Pharm. Res. 2005, 28, 685-690.
31. Sherr, C.J. Cancer cell cycles. Science 1996, 274, 1672-1677.
32. Sherr, C.J. Cell cycle control and cancer. Harvey Lect. 2000, 96, 73-92.
33. Taylor, W.R.; Stark, G.R. Regulation of the G2/M transition by p53. Oncogene 2001, 20, 1803-1815.
34. Diehl, J.A.; Cheng, M.; Roussel, M.F.; Sherr, C.J. Glycogen synthase kinase-3ß regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 1998, 12, 3499-3511.
35. Carlson, B.; Lahusen, T.; Singh, S.; Loaiza-Perez, A.; Worland, P.J.; Pestell, R.; Albanese, C.; Sausville, E.A.; Senderowicz, A.M. Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res. 1999, 59, 4634-4641.
36. Yu, Q.; Geng, Y.; Sicinski, P. Specific protection against breast cancers by cyclin D1 ablation. Nature 2001, 411, 1017-1021.
37. Hall, M.; Peters, G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv. Cancer Res. 1996, 68, 67-108.
38. Levesque, A.A.; Eastman, A. p53-based cancer therapies: Is defective p53 the Achilles heel of the tumor? Carcinogenesis 2007, 28, 13-20.
39. Harris, S.L.; Levine, A.J. The p53 pathway: Positive and negative feedback loops. Oncogene 2005, 24, 2899-2908.
40. Kohn, K.W. Molecular interaction map of the mammalian cell cycle control and DNA repair systems. Mol. Biol. Cell 1999, 10, 2703-2734.
41. El-Deiry, W.S.; Harper, J.W.; O'Connor, P.M.; Velculescu, V.E.; Canman, C.E.; Jackman, J.; Pietenpol, J.A.; Burrell, M.; Hill, D.E.; Wang, Y.; et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 1994, 54, 1169-1174.
42. Waldman, T.; Kinzler, K.W.; Vogelstein, B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res. 1995, 55, 5187-5190.
43. Eastman, A. Cell cycle checkpoints and their impact on anticancer therapeutic strategies. J. Cell Biochem. 2004, 91, 223-231.
44. Samuel, T.; Weber, H.O.; Funk, J.O. Linking DNA damage to cell cycle checkpoints. Cell Cycle 2002, 1, 162-168.
45. Iliakis, G.; Wang, Y.; Guan, J.; Wang, H. DNA damage checkpoint control in cells exposed to ionizing radiation. Oncogene 2003, 22, 5834-5847.
46. He, G.; Kuang, J.; Khokhar, A.R.; Siddik, Z.H. The impact of S-and G2-checkpoint response on the fidelity of G1-arrest by cisplatin and its comparison to a non-cross-resistant platinum(IV) analog. Gynecol. Oncol. 2011, 122, 402-409.
47. Iavarone, A.; Massague, J. Repression of the CDK activator Cdc25A and cell-cycle arrest by cytokine TGF-beta in cells lacking the CDK inhibitor p15. Nature 1997, 387, 417-422.
48. Luo, X.; Chen, J.; Song, W.X.; Tang, N.; Luo, J.; Deng, Z.L.; Sharff, K.A.; He, G.; Bi, Y.; He, B.C.; et al. Osteogenic BMPs promote tumor growth of human osteosarcomas that harbor differentiation defects. Lab. Invest. 2008, 88, 1264-1277.
49. He, B.C.; Chen, L.; Zuo, G.W.; Zhang, W.; Bi, Y.; Huang, J.; Wang, Y.; Jiang, W.; Luo, Q.; Shi, Q.; et al. Synergistic antitumor effect of the activated PPAR. and retinoid receptors on human osteosarcoma. Clin. Cancer Res. 2010, 16, 2235-2245.
50. He, B.C.; Gao, J.L.; Zhang, B.Q.; Luo, Q.; Shi, Q.; Kim, S.H.; Huang, E.; Gao, Y.; Yang, K.; Wagner, E.R.; et al. Tetrandrine inhibits Wnt/ß-catenin signaling and suppresses tumor growth of human colorectal cancer. Mol. Pharmacol. 2011, 79, 211-219.